Roivant Sciences Ltd. (DE:87S)
NASDAQ:87S
Total Valuation
Roivant Sciences has a market cap or net worth of €17.49B. The enterprise value is €20.26B.
Market Cap€17.49B
Enterprise Value€20.26B
Share Statistics
Roivant Sciences has 719,270,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding719,270,400
Owned by Insiders19.98%
Owned by Institutions21.20%
Financial Efficiency
Roivant Sciences’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -23.55%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-23.55%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee9.10K
Profits Per Employee-438.22K
Employee Count908
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Roivant Sciences is ―. Roivant Sciences’s PEG ratio is -0.81.
PE Ratio―
PS Ratio2326.88
PB Ratio4.25
Price to Fair Value4.25
Price to FCF-25.34
Price to Operating Cash Flow-26.43
PEG Ratio-0.81
Income Statement
In the last 12 months, Roivant Sciences had revenue of 8.26M and earned -299.77M in profits. Earnings per share was -0.43.
Revenue8.26M
Gross Profit6.97M
Operating Income-1.29B
Pretax Income-264.58M
Net Income-299.77M
EBITDA-1.28B
Earnings Per Share (EPS)-0.43
Cash Flow
In the last 12 months, operating cash flow was -750.35M and capital expenditures -8.21M, giving a free cash flow of -758.56M billion.
Operating Cash Flow-750.35M
Free Cash Flow-758.56M
Free Cash Flow per Share-1.05
Dividends & Yields
Roivant Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.41
52-Week Price Change156.72%
50-Day Moving Average24.26
200-Day Moving Average18.77
Relative Strength Index (RSI)58.53
Average Volume (3m)13.00
Important Dates
Roivant Sciences upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).
Last Earnings DateMay 20, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Roivant Sciences as a current ratio of 18.37, with Debt / Equity ratio of 2.37%
Current Ratio18.37
Quick Ratio18.37
Debt to Market Cap<0.01
Net Debt to EBITDA1.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Roivant Sciences has paid 133.33M in taxes.
Income Tax133.33M
Effective Tax Rate-0.50
Enterprise Valuation
Roivant Sciences EV to EBITDA ratio is -13.97, with an EV/FCF ratio of -23.60.
EV to Sales2.17K
EV to EBITDA-13.97
EV to Free Cash Flow-23.60
EV to Operating Cash Flow-23.86
Balance Sheet
Roivant Sciences has €4.30B in cash and marketable securities with €107.44M in debt, giving a net cash position of €4.19B billion.
Cash & Marketable Securities€4.30B
Total Debt€107.44M
Net Cash€4.19B
Net Cash Per Share€5.82
Tangible Book Value Per Share€7.63
Margins
Gross margin is 84.44%, with operating margin of -15560.57%, and net profit margin of -3629.19%.
Gross Margin84.44%
Operating Margin-15560.57%
Pretax Margin-3203.12%
Net Profit Margin-3629.19%
EBITDA Margin-15520.04%
EBIT Margin-15560.57%
Analyst Forecast
The average price target for Roivant Sciences is €32.51, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€32.51
Price Target Upside32.71% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―